Jounce Therapeutics

Jounce Therapeutics is dedicated to transforming the treatment of cancer

Jounce is a physics term and refers to a major jolt in a new direction, in this case, leading to a paradigm shift in drug discovery, development and treatment for cancer.

We are discovering and developing novel cancer immunotherapies linked to patient selection strategies that are designed to mobilize the immune system to seek out and attack cancerous cells and tumors. Our translational science-based product engine has the potential to discover novel biological insights to drive the development of game-changing immunotherapy treatments with highly durable responses, extending and improving patients' quality of life.

Jounce News


Jounce Therapeutics Announces Presentation at the Leerink Partners Immuno-Oncology Roundtable

Read More > >


Jounce Therapeutics Appoints Kim Drapkin, CPA as Chief Financial Officer

Read More > >


Lasker Foundation Gives Jounce Founder, James Allison, 2015 Lasker Award

Read More > >


Jounce Therapeutics to Present at the Bank of America Merrill Lynch 2015 Health Care Conference

Read More > >


Jounce Therapeutics Secures $56 Million in Oversubscribed Series B Financing

Read More > >


Jounce Therapeutics to Present at the Jefferies 2015 Immuno-Oncology Summit

Read More > >


Jounce Therapeutics to Present at the Cowen and Company 35th Annual Health Care Conference

Read More > >


Jounce Therapeutics Appoints Deborah Law, D. Phil., to Chief Scientific Officer

Read More > >